Evidence map›Paper›PMID 40646314›Full record

ArticleJournal of gastrointestinal cancer2025

Endoscopic Submucosal Dissection Followed by Chemoradiotherapy Versus Radiotherapy in Patients with Stage T1bN0M0 Esophageal Cancer.

Yan Lin, Cheng-Xian Ma, Huan-Wei Liang, Wei Huang, Xin-Bin Pan

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan LinDepartment of Gastroenterology, Jiangbin Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530000, People's Republic of China.
Cheng-Xian MaDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Qingxiu District, No. 71 Hedi Road, Nanning, Guangxi, 530021, People's Republic of China.
Huan-Wei LiangDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Qingxiu District, No. 71 Hedi Road, Nanning, Guangxi, 530021, People's Republic of China.
Wei HuangDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Qingxiu District, No. 71 Hedi Road, Nanning, Guangxi, 530021, People's Republic of China.
Xin-Bin PanDepartment of Radiation Oncology, Guangxi Medical University Cancer Hospital, Qingxiu District, No. 71 Hedi Road, Nanning, Guangxi, 530021, People's Republic of China. panxinbin@gxmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare survival outcomes between endoscopic submucosal dissection (ESD) followed by chemoradiotherapy versus radiotherapy in stage T1bN0M0 esophageal cancer. MATERIALS AND

methodsPatients with stage T1bN0M0 esophageal cancer between 2000 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Cancer-specific survival (CSS) and overall survival (OS) were compared between the ESD followed by chemoradiotherapy versus radiotherapy cohorts.

resultsAmong 71 eligible patients, 57 (80.3%) received ESD followed by chemoradiotherapy and 14 (19.7%) underwent ESD followed by radiotherapy. Before propensity score matching, ESD followed by radiotherapy demonstrated inferior 5-year CSS (hazard ratio [HR] = 3.27, 95% confidence interval [CI] 1.12-9.58, P = 0.030), but comparable 5-year OS (HR = 1.46; 95% CI, 0.65-3.27; P = 0.362) versus ESD followed by chemoradiotherapy. After propensity score matching, no significant difference in 5-year CSS (HR = 1.76; 95% CI, 0.49-6.34; P = 0.386) or OS (HR = 1.33; 95% CI, 0.48-3.74; P = 0.585) was observed between treatment groups.

conclusionESD followed by radiotherapy provides equivalent CSS and OS compared to ESD followed by chemoradiotherapy in patients with stage T1bN0M0 esophageal cancer.

Indexed as

ChemoradiotherapyEndoscopic Mucosal ResectionEsophageal NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm StagingPropensity ScoreRetrospective StudiesSEER ProgramSurvival RateChemoradiotherapyEndoscopic submucosal dissectionEsophageal cancerRadiotherapySurvival analysisT1bN0M0

Identifiers

PMID40646314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.